

1638

**LAHIVE & COCKFIELD LLP**  
COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
lc@lahive.com

**RECEIVED**  
FEB 28 2002

TECH CENTER 1600/2900

JOHN A. LAHIVE, JR. (1928-1997)  
THOMAS V. SMURZYNSKI  
RALPH A. LOREN  
GIULIO A. DeCONTI, JR.  
ANN LAMPORT HAMMITTE  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
DeANN FORAN SMITH  
PETER C. LAURO  
JEANNE M. DIGIORGIO  
DEBRA J. MILASINCIC, Ph.D.  
DAVID J. RIKKERS  
DAVID R. BURNS  
JOHN S. CURRAN  
SEAN D. DETWEILER

CYNTHIA L. KANIK, Ph.D.  
MEGAN E. WILLIAMS, Ph.D.  
RICHA NAND  
MICHAEL PHILLIPPS \*  
USA M. DIROCCO  
HATHAWAY P. RUSSELL \*\*  
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.  
PETER A. DIMATTIA  
VINCENT P. LOCCISANO  
MERIDETH C. ARNOLD

**SENIOR COUNSEL**  
JAMES E. COCKFIELD

**OF COUNSEL**  
JEREMIAH LYNCH  
WILLIAM A. SCOFIELD, JR.  
SIBLEY P. REPPERT

**TECHNICAL SPECIALISTS**  
CYNTHIA M. SOROOS  
PETER W. DINI, Ph.D.  
EUIHOON LEE  
JENNIFER K. ROSENFELD  
ALLAN TAMESHTIT, Ph.D.  
CATHERINE E. McPHERSON  
ERIC F. WAGNER, Ph.D.  
SHAHID HASAN, Ph.D.  
JACOB G. WEINTRAUB  
JONATHAN M. SPARKS, Ph.D.  
CRISTIN E. HOWLEY, Ph.D.

\* Admitted in NY only  
\*\* Admitted in TX only

**PATENT AGENTS**  
THEODORE R. WEST  
SHAYNE Y. HUFF, Ph.D.  
DANIEL B. KO

Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Patent Application No.: 09/851,614  
*Human Monoclonal Antibodies to Dendritic Cells*  
Inventor: Yashwant M. Deo et al.  
Filed: May 8, 2001  
Our Ref. No.: MXI-166


Dear Sir:


I enclose herewith for filing in the above-identified application the following:


1. Information Disclosure Statement;
2. PTO Form 1449;
3. Copies of references cited in PTO Form 1449; and
4. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

February 11, 2002  
Date:   
Jane E. Remillard, Esquire, Reg. No. 38,872

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP  
  
Jane E. Remillard, Esquire  
Registration No. 38,872  
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IDS/#6  
2/3/01/02

In re the application of: Yashwant M. Deo et al.

Serial No.: 09/851,614

Filed: May 8, 2001

For: *Human Monoclonal Antibodies to Dendritic Cells*

Attorney Docket No.: MXI-166

Group Art Unit: 1638

Examiner:

RECEIVED  
FEB 28 2002  
TECH CENTER 1600/2900

Commissioner for Patents  
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

February 11, 2002

Date of Signature and of Mail Deposit

By:


Jane E. Remillard, Esquire  
Registration No. 38,872  
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.


This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be



construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP



Jane E. Remillard, Esquire  
Registration No. 38,872  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
(617) 227-7400

Date: February 11, 2002

GAD/JER/RKN/alf  
Enclosures